… States is not well documented. In this study, we assessed the prevalence of MH in New York
State … HCUP SID files for New York State from 2001 to 2005 were used in this study. The …

… Prevalence per 100,000 discharges and SE of malignant hyperthermia due to anesthesia
by surgical procedure category in ambulatory surgery centers, New York State, 2002 to 2007. …

… A study of 12 million hospital discharges in the state of New York demonstrated the prevalence
of MH to be one in 100,000 surgical procedures although the type of anesthetic was not …

… Malignant hyperthermia (MH) is a rare yet potentially fatal pharmacogenetic disorder
triggered by exposure to inhalational anesthetics and the depolarizing neuromuscular blocking …

… Each clinical finding is weighted as to significance in being associated with MHS as
determined by malignant hyperthermia (MH) experts using a Delphi method. Points are assigned …

… The Malignant Hyperthermia Association of the United States … and scientific understanding
of malignant hyperthermia (MH) … the Malignant Hyperthermia Association of the United States …

… Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic disorder with an estimated
mortality of less than 5%. The purpose of this study was to evaluate the current incidence …

… In 1997, the International Classification of Diseases (ICD), 9th Revision Clinical Modification
(ICD-9) coding system introduced the code for malignant hyperthermia (MH) (995.86). The …

… Once a proband has been determined to be susceptible to malignant hyperthermia (MH) by
a clinical episode plus either a positive caffeine-halothane contracture test (CHCT) result or …

… These cases may or may not have been discussed with Malignant Hyperthermia Association
of the United States hotline consultants, and in most cases, we suspect that the final …